Payment overview · 2025
General Payments
$97.45
5 reported records · 4 companies
Healthcare provider profile · identity verified
Raymond Tran, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LINCOLNTON, NC · NPI 1548286925
Verified facts
What the public records show
CMS Open Payments records show Raymond Tran, MD received $97.45 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 41.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.64 | 41.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.12 | 20.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.32 | 19.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.37 | 17.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.45 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
186 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 693 | 176 |
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 534 | 139 |
| Omeprazole | Omeprazole | 493 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 97 |
| Meloxicam | Meloxicam | 351 | 107 |
| Fluticasone Propionate | Fluticasone Propionate | 328 | 118 |
| Simvastatin | Simvastatin | 324 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 81 |
| Metformin Hcl | Metformin Hcl | 286 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 276 | 71 |
| Gabapentin | Gabapentin | 248 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 66 |
| Losartan Potassium | Losartan Potassium | 215 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 56 |
| Allopurinol | Allopurinol | 204 | 49 |
| Metformin Hcl Er | Metformin Hcl | 201 | 44 |
| Jardiance | Empagliflozin | 186 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 56 |
| Trazodone Hcl | Trazodone Hcl | 170 | 49 |
| Tramadol Hcl | Tramadol Hcl | 165 | 41 |
| Montelukast Sodium | Montelukast Sodium | 160 | 38 |
| Prednisone | Prednisone | 154 | 135 |
| Furosemide | Furosemide | 137 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 37 |
| Eliquis | Apixaban | 122 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 24 |
| Potassium Chloride | Potassium Chloride | 107 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 38 |
| Carvedilol | Carvedilol | 93 | 27 |
| Glimepiride | Glimepiride | 84 | 19 |
| Sertraline Hcl | Sertraline Hcl | 83 | 23 |
| Ozempic | Semaglutide | 82 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 16 |
| Lovastatin | Lovastatin | 71 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 16 |
| Buspirone Hcl | Buspirone Hcl | 65 | 22 |
| Famotidine | Famotidine | 65 | 19 |
| Januvia | Sitagliptin Phosphate | 62 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 14 |
| Bupropion Xl | Bupropion Hcl | 59 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 58 |
| Fenofibrate | Fenofibrate | 59 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 53 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 41 |
| Celecoxib | Celecoxib | 46 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 12 |
| Alprazolam | Alprazolam | 44 | suppressed |
| Atenolol | Atenolol | 44 | 11 |
| Mirtazapine | Mirtazapine | 44 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Colchicine | Colchicine | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 13 |
| Sucralfate | Sucralfate | 40 | 14 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 16 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 26 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 11 |
| Torsemide | Torsemide | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 20 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Ondansetron Odt | Ondansetron | 31 | 26 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 11 |
| Nystatin | Nystatin | 24 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Linzess | Linaclotide | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $97.45 · 5 records | Novo Nordisk Inc | AREXVY, BEXSERO, BREZTRI, MOUNJARO, SHINGRIX, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error